Enhancing immunotherapy efficacy of hepatocellular carcinoma by inhibiting the key antioxidant factor Nrf2
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201225
DOI: 10.1016/j.omton.2026.201225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Yan Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universidade de Macau, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) responds poorly to immune checkpoint inhibitors (ICIs), with fewer than 20% of patients deriving clinical benefit. In our recent article, “targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in HCC1” published in the Journal for ImmunoTherapy of Cancer, we show that nuclear factor erythroid 2-related factor 2 (Nrf2), a master antioxidant transcription factor, acts as a dual suppressor of antitumor immunity in HCC by simultaneously driving programmed death ligand-1 (PD-L1) expression and silencing major histocompatibility complex class I (MHC-I) on tumor cells.
Autor:innen und Institutionen
- Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, China.
- Cancer Centre, Department of Biomedical Sciences, Faculty of Health Sciences & MoE Frontiers Science Centre for Precision Oncology, University of Macau, Avenida da Universidade, Taipa, Macau SAR, PR China.
Förderung
- Universidade de Macau
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
Zitieren
APA
Zhu, Y., Liu, M., Kwok, H. F., & Chen, L. (2026). Enhancing immunotherapy efficacy of hepatocellular carcinoma by inhibiting the key antioxidant factor Nrf2. Molecular Therapy Oncology, 34(2), 201225. https://doi.org/10.1016/j.omton.2026.201225
Vancouver
Zhu Y, Liu M, Kwok HF, Chen L. Enhancing immunotherapy efficacy of hepatocellular carcinoma by inhibiting the key antioxidant factor Nrf2. Molecular Therapy Oncology. 2026;34(2):201225. doi:10.1016/j.omton.2026.201225
BibTeX
@article{Zhu2026,
author = {Zhu, Yan and Liu, Maoxuan and Kwok, Hang Fai and Chen, Liang},
title = {Enhancing immunotherapy efficacy of hepatocellular carcinoma by inhibiting the key antioxidant factor Nrf2},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201225},
doi = {10.1016/j.omton.2026.201225}
}
EUVIMED